Roche’s Genentech has broken ground on a new US manufacturing site in Holly Springs, North Carolina, Genentech’s first manufacturing facility on the East Coast. The 65,000-square-meter facility is designed to support production of the company’s future portfolio of metabolic medicines, including treatments for obesity.  

The new facility is expected to be completed and operational by 2029, incorporating modern biomanufacturing technologies, as well as advanced automation and digital capabilities. The 400,000-m² lot includes space for future expansion. 

Genentech’s initial investment in North Carolina is estimated at more than $700 million and is part of Roche’s $50-billion commitment to invest in US manufacturing infrastructure and R&D. The new facility will create more than 1,900 jobs. 

Source: Roche